Scientist and neurologist Dr. Dr. Lukas Bunse received the Hella Bühler Award, which is endowed with €100,000. The award aims at young researchers at Heidelberg University with outstanding scientific engagement in cancer research. Lukas Bunse is conducting research in the field of brain tumor immunology.
Lukas Bunse studied medicine at the University of Heidelberg and University College London (UK). At Ruperto Carola, he submitted his medical doctoral thesis on specific spontaneous immune responses of patients with gliomas. He then worked as a postdoctoral fellow in the Department of Neurology at Heidelberg University Hospital. In parallel, he conducted research at the Faculty of Biosciences at the University of Heidelberg and at the German Cancer Research Center. There, he wrote another doctoral thesis in biology, which he completed in 2020. Since 2019, Dr. Bunse has been working at the Neurological Clinic of the University Hospital Mannheim. As a research group leader, he investigates brain tumor-typical mechanisms of immune resistance in order to develop new approaches for combined immunotherapies.
Lukas Bunse's work was honored at the awards ceremony at the Marsilius-Arkaden Heidelberg on May 17, 2022. Prof. Dr. Michael Platten, Director of the Department of Neurology at the University Hospital Mannheim and Head of the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center, delivered the laudatory speech for Dr. Bunse. Lukas Bunse then explained his current research.
Press release at Heidelberg University (German language)
- Friedrich M, Hahn M, Michel J, […], Bunse L. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro Oncol. 2022. doi: 10.1093/neuonc/noac138 Online ahead of print
- Bunse L, Rupp AK, Poschke I, […], Platten M. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurol Res Pract. 202 4(1):20. doi: 10.1186/s42466-022-00184-x
- Friedrich M, Kehl N, Engelke N, […], Bunse L. Intrathecal activation of CD8+ memory T cells in IgG4-related disease of the brain parenchyma. EMBO Mol Med. 2021. 13(8):e1395 doi: 10.15252/emmm.202113953
- Platten M, Bunse L, Wick A, […], Wick W. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021. 592(7854):463-468. doi: 10.1038/s41586-021-03363-z
- Friedrich M*, Sankowski R*, Bunse L*, […], Prinz M*, Platten M*. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nature Cancer. 2021. 2(7):723-740. doi: 10.1038/s43018-021-00201-z *Co-authors
- Aslan K, Turco V, Blobner J, […], Bunse L, […], Platten M. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun. 2020. 11(1):931. doi: 10.1038/s41467-020-14642-0
- Bunse L, Green EW, Platten M. High-throughput discovery of cancer-targeting TCRs. Methods Enzymol. 2019. 629:401-41 doi: 10.1016/bs.mie.2019.10.00
- Hilf N, Kuttruff-Coqui S, Frenzel K, […], Bunse L, […], Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019. 565(7738):240-245. doi: 10.1038/s41586-018-0810-y
- Bunse L*, Pusch S*, Bunse T*, […], Platten M. Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. Nat Med. 2018. 24(8):1192-1203. doi: 10.1038/s41591-018-0095-6 *Co-authors
- Rothhammer V, Mascanfroni ID, Bunse L, […], Quintana FQ. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016. 22(6):586-97. doi: 1038/nm.4106
- Bunse L*, Schumacher T*, Sahm F*, […], Platten M. In situ proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest. 2015. 125(2):593-606. doi: 10.1172/JCI77780 *Co-authors
- Schumacher T*, Bunse L*, Pusch S, […], Platten M. A vaccine targeting mutant IDH1 induces antitumor immunity. Nature. 2014. 21;512(7514):324-7. doi: 10.1038/nature13387 *Co-authors